title: Discovery of the first small-molecule opioid pan antagonist with nanomolar affinity at mu, delta, kappa, and nociceptin opioid receptors.
abstract: The trans-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine scaffold is a known pharmacophore for mu opioid (MOP), kappa opioid (KOP), and delta opioid (DOP) receptor antagonists; however, it has not been explored in nociceptin opioid (NOP/ORL-1) receptor ligands. We recently found that the selective KOP antagonist JDTic, (3R)-7-hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide, containing this opioid antagonist pharmacophore, has significant binding affinity at the NOP receptor (Ki 16.67 ± 0.76 nM), with no intrinsic activity in the [(35)S]GTPγS functional assay. Since this is the first ligand containing the trans-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonist pharmacophore to have affinity for the NOP receptor, we explored the structural determinants of its NOP binding affinity. When rational chemical modifications of JDTic were carried out, based on our previously established NOP pharmacophoric structure-activity relationship (SAR) model, most modifications led to a significant decrease in NOP and opioid binding affinity compared to JDTic. Interestingly, however, removal of the 3,4-dimethyl groups of the trans-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine antagonist scaffold of JDTic increased the binding affinity at NOP by 10-fold (Ki 1.75 ± 0.74 nM) while maintaining comparable affinity for KOP, MOP, and DOP receptors (Ki 1.14 ± 0.63, 1.67 ± 0.6, and 19.6 ± 1.3 nM, respectively). In vitro functional efficacy studies using the [(35)S]GTPγS assay showed that this compound AT-076 functions as an antagonist at all four opioid receptors. Detailed characterization of the antagonist activity of AT-076 shows that it has a noncompetitive antagonist profile at the NOP and KOP receptors (insurmountable antagonism), but is a potent competitive antagonist at the MOP and DOP receptors, with Ke values 3-6-fold more potent than those of JDTic. AT-076 is the first opioid pan antagonist with high affinity at all four opioid receptor subtypes. Our SAR studies show that the 3,4-dimethyl groups of the well-known trans-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonist scaffold may be removed without significant loss in binding affinity or antagonist potency to obtain an opioid pan antagonist such as AT-076.
authors: †Astraea Therapeutics, 320 Logue Avenue, Suite 142, Mountain View, California 94043, United States.
authors: Nurulain T
authors: NT
authors: Zaveri
authors: †Astraea Therapeutics, 320 Logue Avenue, Suite 142, Mountain View, California 94043, United States.
authors: V Blair
authors: VB
authors: Journigan
authors: ‡SRI International, Biosciences, 333 Ravenswood Avenue, Menlo Park, California 94025, United States.
authors: Willma E
authors: WE
authors: Polgar
mesh_terms: D000701:Analgesics, Opioid / Q000737:chemistry / Q000494:pharmacology; D000818:Animals; D016466:CHO Cells; D002462:Cell Membrane / Q000187:drug effects / Q000378:metabolism; D003412:Cricetulus; D004305:Dose-Response Relationship, Drug; D016244:Guanosine 5'-O-(3-Thiotriphosphate) / Q000737:chemistry; D006801:Humans; D008956:Models, Chemical; D015394:Molecular Structure; D009292:Narcotic Antagonists / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D010880:Piperidines / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D011485:Protein Binding; D011957:Receptors, Opioid / Q000378:metabolism; D017465:Receptors, Opioid, delta / Q000037:antagonists & inhibitors* / Q000378:metabolism; D017473:Receptors, Opioid, kappa / Q000037:antagonists & inhibitors* / Q000378:metabolism; D017450:Receptors, Opioid, mu / Q000037:antagonists & inhibitors* / Q000378:metabolism; D013462:Sulfur Radioisotopes / Q000737:chemistry; D044005:Tetrahydroisoquinolines / Q000737:chemistry / Q000494:pharmacology; D014162:Transfection; D000094942:Nociceptin Receptor
chemical_list: C488414:3,4-dimethyl-4-(3-hydroxyphenyl)piperidine; C433814:7-hydroxy-N-(1-((4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl)methyl)-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide; D000701:Analgesics, Opioid; D009292:Narcotic Antagonists; D010880:Piperidines; D011957:Receptors, Opioid; D017465:Receptors, Opioid, delta; D017473:Receptors, Opioid, kappa; D017450:Receptors, Opioid, mu; D013462:Sulfur Radioisotopes; D044005:Tetrahydroisoquinolines; D016244:Guanosine 5'-O-(3-Thiotriphosphate); D000094942:Nociceptin Receptor
keywords: JDTic; NOP; nociceptin antagonist; nociceptin ligand; opioid antagonist; pan antagonist
references: Br J Pharmacol. 2008 Feb;153(3):609-19
references: 18059322
references: Med Res Rev. 2011 Jul;31(4):605-48
references: 20099319
references: Nature. 2012 May 17;485(7398):321-6
references: 22437502
references: Nature. 2012 May 17;485(7398):327-32
references: 22437504
references: Nature. 2012 May 17;485(7398):395-9
references: 22596163
references: Nature. 2012 May 17;485(7398):400-4
references: 22596164
references: PLoS One. 2013;8(8):e70701
references: 23976952
references: J Med Chem. 2014 Apr 10;57(7):3140-7
references: 24635568
references: ChemMedChem. 2014 Aug;9(8):1638-54
references: 24981721
references: J Med Chem. 1999 Dec 16;42(25):5061-3
references: 10602690
references: J Med Chem. 2001 Aug 16;44(17):2687-90
references: 11495579
references: Eur J Pharmacol. 2001 Sep 28;428(1):29-36
references: 11779034
references: Life Sci. 2003 Jun 27;73(6):663-78
references: 12801588
references: J Med Chem. 2003 Jul 3;46(14):3127-37
references: 12825951
references: J Pharmacol Exp Ther. 2004 Feb;308(2):454-61
references: 14593080
references: J Med Chem. 2004 Feb 12;47(4):1070-3
references: 14761209
references: J Med Chem. 2004 Jun 3;47(12):2973-6
references: 15163178
references: Eur J Pharmacol. 2004 Oct 6;501(1-3):111-9
references: 15464069
references: Biochem Pharmacol. 1973 Dec 1;22(23):3099-108
references: 4202581
references: Nature. 1978 Sep 28;275(5678):332-4
references: 692714
references: J Med Chem. 1993 Oct 1;36(20):2833-41
references: 8410998
references: J Med Chem. 1993 Oct 1;36(20):2842-50
references: 8410999
references: FEBS Lett. 1994 Mar 14;341(1):33-8
references: 8137918
references: J Med Chem. 1994 Jul 22;37(15):2262-5
references: 8057274
references: Mol Pharmacol. 1995 Apr;47(4):848-54
references: 7723747
references: J Biol Chem. 1996 Dec 13;271(50):32016-20
references: 8943250
references: J Pharmacol Exp Ther. 1997 Nov;283(2):735-41
references: 9353393
references: Neuropeptides. 1997 Oct;31(5):403-8
references: 9413015
references: Mol Pharmacol. 1998 Apr;53(4):772-7
references: 9547370
references: NIDA Res Monogr. 1998 Mar;178:440-66
references: 9686407
references: J Med Chem. 1998 Dec 17;41(26):5188-97
references: 9857089
references: Br J Pharmacol Chemother. 1959 Mar;14(1):48-58
references: 13651579
references: AAPS J. 2005;7(2):E345-52
references: 16353914
references: J Pharmacol Exp Ther. 2006 Nov;319(2):710-23
references: 16857731
references: Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33
references: 17420123
references: Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7
references: 17428659